159 related articles for article (PubMed ID: 6814151)
1. Biosynthesis of immunoglobulin in human immunoproliferative diseases. II. Comparison of tumour cell mass in multiple myeloma measured by synthetic rate studies with that calculated from clinical staging systems.
Cooper DA; Miller AC; Penny R
Acta Haematol; 1982; 68(3):224-36. PubMed ID: 6814151
[TBL] [Abstract][Full Text] [Related]
2. Monitoring myelomatosis.
Hobbs JR
Arch Intern Med; 1975 Jan; 135(1):125-30. PubMed ID: 1111461
[TBL] [Abstract][Full Text] [Related]
3. Cytology of myeloma cells.
Hayhoe FG; Neuman Z
J Clin Pathol; 1976 Oct; 29(10):916-22. PubMed ID: 824323
[TBL] [Abstract][Full Text] [Related]
4. Biosynthesis of immunoglobulin in human immunoproliferative diseases. I. Kinetics of synthesis and secretion of immunoglobulin and protein by bone marrow cells in myeloma.
Hammerton K; Cooper DA; Duckett M; Penny R
J Immunol; 1978 Aug; 121(2):409-17. PubMed ID: 681741
[No Abstract] [Full Text] [Related]
5. [Isotypic characterization of IgA paraproteins: association with other clinical and analytic data].
González González JB; García Delgado R; Cámara Sáez E; Ortiz Maslloréns F
Rev Clin Esp; 1996 Aug; 196(8):529-35. PubMed ID: 8984539
[TBL] [Abstract][Full Text] [Related]
6. Synthesis and metabolism of Bence Jones protein and calculation of tumour burden in patients with Bence Jones myeloma.
Durie BG; Cole PW; Chen HS; Himmelstein KJ; Salmon SE
Br J Haematol; 1981 Jan; 47(1):7-19. PubMed ID: 7437347
[TBL] [Abstract][Full Text] [Related]
7. IgD multiple myeloma. Review of 133 cases.
Jancelewicz Z; Takatsuki K; Sugai S; Pruzanski W
Arch Intern Med; 1975 Jan; 135(1):87-93. PubMed ID: 1111472
[TBL] [Abstract][Full Text] [Related]
8. Comparison of new patients with Bence-Jones, IgG and IgA myeloma receiving sequential therapy: the need to regard these immunologic subtypes as separate disease entities with specific prognostic criteria.
Sirohi B; Powles R; Kulkarni S; Rudin C; Saso R; Lal R; Singhal S; Mehta J; Horton C; Treleaven J
Bone Marrow Transplant; 2001 Jul; 28(1):29-37. PubMed ID: 11498741
[TBL] [Abstract][Full Text] [Related]
9. Hypoalbuminemia in patients with multiple myeloma.
Chen YH; Magalhaes MC
Arch Intern Med; 1990 Mar; 150(3):605-10. PubMed ID: 2310279
[TBL] [Abstract][Full Text] [Related]
10. Significance of M-components in plasma cell myeloma and related disorders.
Kano T
Tohoku J Exp Med; 1970 Dec; 102(4):341-67. PubMed ID: 4101555
[No Abstract] [Full Text] [Related]
11. A new improved clinical staging system for multiple myeloma based on analysis of 123 treated patients.
Merlini G; Waldenström JG; Jayakar SD
Blood; 1980 Jun; 55(6):1011-9. PubMed ID: 7378577
[TBL] [Abstract][Full Text] [Related]
12. Multiple myeloma: quantitative staging and assessment of response with a programmable pocket calculator.
Salmon SE; Wampler SB
Blood; 1977 Mar; 49(3):379-89. PubMed ID: 836948
[TBL] [Abstract][Full Text] [Related]
13. [Clinical and quantitative staging and monitoring of multiple myeloma. Analysis of 145 clinical cases].
Di Guglielmo R; Vercelli D; Guidi G
Recenti Prog Med; 1979 Apr; 66(4):382-417. PubMed ID: 482726
[No Abstract] [Full Text] [Related]
14. Immunochemical Diagnosis of Multiple Myeloma.
Lyubimova NV; Timofeev YS; Abaev VM; Votyakova OM; Kushlinskii NE
Bull Exp Biol Med; 2018 May; 165(1):84-87. PubMed ID: 29797132
[TBL] [Abstract][Full Text] [Related]
15. [Anatomo-morphological characteristics of different protein types in myelomas (IgG, IgA and Bence Jones)].
Voĭno-Iasenetskaia OV
Probl Gematol Pereliv Krovi; 1974 Aug; 19(8):34-6. PubMed ID: 4408561
[No Abstract] [Full Text] [Related]
16. [Prognostic factors affecting survival in multiple myeloma].
Tornóczky J; Tóth A; Sziládi E; Hoffmann E; Liszátz M
Orv Hetil; 1990 Aug; 131(31):1679-84. PubMed ID: 2205822
[TBL] [Abstract][Full Text] [Related]
17. Determination of plasma cell secreting potential as an index of maturity of myelomatous cells and a strong prognostic factor.
Symeonidis A; Kouraklis-Symeonidis A; Grouzi E; Zolota V; Melachrinou M; Kourea K; Fragopanagou E; Giannakoulas N; Seimeni U; Tiniakou M; Matsouka P; Zoumbos N
Leuk Lymphoma; 2002 Aug; 43(8):1605-12. PubMed ID: 12400603
[TBL] [Abstract][Full Text] [Related]
18. Immunoglobulin synthesis and total body tumor cell number in IgG multiple myeloma.
Salmon SE; Smith BA
J Clin Invest; 1970 Jun; 49(6):1114-21. PubMed ID: 4987170
[TBL] [Abstract][Full Text] [Related]
19. [Prognostic factors in IgG and micromolecular multiple myeloma. Retrospective analysis of 50 consecutive cases].
Pasqualetti P; Casale R; Colantonio D; Festuccia V; Di Lauro G; Natali G
Minerva Med; 1987 May; 78(9):603-8. PubMed ID: 3587727
[TBL] [Abstract][Full Text] [Related]
20. Subclasses IgG1--IgG4 in 84 sera with IgG paraprotein.
Tichý M; Hrncír Z; Mracek J
Neoplasma; 1978; 25(1):107-10. PubMed ID: 634402
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
